Appolonia Adeyemi 
Fidson Healthcare Plc, one of Nigeria’s foremost pharmaceutical companies, has announced a strategic partnership with Liddie BE Limited, a renowned clinical research organisation, to conduct a Bioequivalence (BE) study on their chewable formulation of Albendazole tablets.
The founder and Chief Executive Officer (CEO) of Fidson Healthcare Plc, Dr. Fidelis Ayebae, who announced the study at a media briefing in Lagos yesterday, said the aim of Fidson is to secure World Health Organisation (WHO) prequalification for the Albendazole tablets manufactured by Fidson.
Albendazole is a U.S. Food and Drug Administration (FDA) approved medication for the treatment of a variety of parasitic worm infections prevalent in Nigeria and many parts of the world.
The BE study will be conducted under stringent regulatory guidelines that meet international standards and will compare the pharmacokinetics of the novel Albendazole formulation with the standard reference.
Although the study is expected to last for 30 days, the WHO prequalification approval could take a maximum of 18 months to get. Speaking at a joint press conference to announce the collaboration, Dr Fidelis Ayebae said:
“This partnership is ground breaking in the advancement of clinical research, being the first bioequivalence study to be conducted in the country.
“We are excited again to be at the forefront of innovation and leadership in the healthcare industry in Nigeria with this landmark effort. This study is a critical step towards the WHO prequalification of our brand of chewable Albendazole tablets.”
